Stock Events

Stock Events

AnaptysBio 

$56.80
37
-$0.66-1.15% Friday 20:00
+$0.00+0%Friday 23:30After hours

Statistics

Day High
56.88
Day Low
56.71
52W High
72.36
52W Low
11.4
Volume
9,473
Avg. Volume
-
Mkt Cap
1.68B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11SepExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-1.84
-1.05
-0.27
0.52
Expected EPS
-0.465
Actual EPS
N/A

Financials

-5.64%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
234.6MRevenue
-13.23MNet Income

Analyst Ratings

80.00Average Price Target
The highest estimate is 95.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ANAB. It's not an investment recommendation.
NVIDIA
11
NVDA
AMD
10
AMD
Netflix
10
NFLX
Walt Disney Co)
10
DIS

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals competes directly with AnaptysBio in the development of antibody therapies for inflammatory diseases.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotech giant that develops treatments in areas overlapping with AnaptysBio's focus, including inflammatory diseases and cancer.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie has a strong portfolio in immunology and oncology, directly competing with AnaptysBio's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a broad focus on immunology and inflammatory diseases, making it a direct competitor in AnaptysBio's market.
Novartis
NVS
Mkt Cap292.35B
Novartis AG competes in the development of innovative medicines in areas including dermatology and rheumatology, overlapping with AnaptysBio's interests.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has a diverse portfolio in oncology and immunology, competing with AnaptysBio in the development of novel therapies.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is involved in the development of drugs for immune-mediated diseases, directly competing with AnaptysBio's pipeline.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad range of products in inflammation and immunology, competing with AnaptysBio in several therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in the same therapeutic areas as AnaptysBio, including immunology.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a strong focus on biopharmaceuticals in areas like respiratory diseases, competing with AnaptysBio's respiratory and inflammatory disease focus.

About

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Show more...
CEO
Daniel Faga
Employees
104
Country
United States
ISIN
US0327241065
WKN
000A2AJ8C

Listings

LSE
GB
0HFQ.LSE
STU
DE
AN6.STU
F
DE
AN6.F
MU
DE
AN6.MU

0 Comments

Share your thoughts

FAQ

What is AnaptysBio stock price today?▼
The current price of ANAB is $56.80 USD — it has decreased by -1.15% in the past 24 hours. Watch AnaptysBio stock price performance more closely on the chart.
What is AnaptysBio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange AnaptysBio stocks are traded under the ticker ANAB.
Is AnaptysBio stock price growing?▼
ANAB stock has risen by +0.92% compared to the previous week, the month change is a +3.29% rise, over the last year AnaptysBio has showed a +159.36% increase.
What is AnaptysBio market cap?▼
Today AnaptysBio has the market capitalization of 1.68B
When is the next AnaptysBio earnings date?▼
AnaptysBio is going to release the next earnings report on September 11, 2026.
What were AnaptysBio earnings last quarter?▼
ANAB earnings for the last quarter are -1.84 USD per share, whereas the estimation was -0.64 USD resulting in a -185.91% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is AnaptysBio revenue for the last year?▼
AnaptysBio revenue for the last year amounts to 234.6M USD.
What is AnaptysBio net income for the last year?▼
ANAB net income for the last year is -13.23M USD.
How many employees does AnaptysBio have?▼
As of September 05, 2026, the company has 104 employees.
In which sector is AnaptysBio located?▼
AnaptysBio operates in the Health & Wellness sector.
When did AnaptysBio complete a stock split?▼
AnaptysBio has not had any recent stock splits.
Where is AnaptysBio headquartered?▼
AnaptysBio is headquartered in SAN DIEGO, United States.